This activity is jointly provided by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC, in Collaboration with the National Organization for Rare Disorders, Inc. (NORD) and the International Fibrodysplasia Ossificans Progressiva Association (IFOPA).

ACKNOWLEDGEMENT

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc

DATE OF RELEASE/EXPIRATION

This activity was released on April 6, 2023 and is valid until August 17, 2024. Requests for credit must be made no later than August 17, 2024.

TARGET AUDIENCE

The educational design of this activity addresses the needs of the primary audience of PCPs, pediatricians, dermatologists, endocrinologists, occupational therapists, oncologists, general practice NPs and PAs, specialist NPs and PAs, and the secondary audience of orthopedists, bone specialists, rheumatologists, pediatric rheumatologists, genetic counselors, and dentists.

STATEMENT OF NEED/PROGRAM OVERVIEW

Fibrodysplasia ossificans progressiva (FOP) causes abnormal bone formation in muscles and soft tissues in episodic “flare-ups” that lead to heterotopic ossification (HO), or replacement of muscle with bone. Ectopic bone formation leads inevitably to severe disability and early death. Because the disease is rare and many clinicians are unfamiliar with its presentation, diagnosis is often missed or delayed by many years. Yet early recognition is crucial to preventing trauma and avoiding medical and surgical interventions that trigger flare-ups and worsen patients’ disability and quality of life. Primary care clinicians have a crucial role in recognizing the condition early and helping patients to avoid triggers

Join a panel of expert clinicians, a patient with FOP and/or their caregiver, and a representative from the International FOP Association (IFOPA) for an interactive dialogue. Panelists will share their experiences with FOP to help clinicians better recognize its hallmark signs and symptoms, make an early and accurate diagnosis, provide appropriate referrals, and offer the most current standard of care.

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

• Recognize early hallmark signs and symptoms that may be conducive to a diagnosis of FOP
• Describe the impacts of FOP on patients’ and caregivers’ quality of life over the disease course
• Develop strategies to work with patients and caregivers to reduce risk of trauma and recognize flare ups early to initiate the recommended management plan

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING EDUCATION

PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 60 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 75% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

FACULTY AND DISCLOSURE OF CONFLICTS OF INTEREST

PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Name of Faculty or Presenter	Conflicts of Interest
Edward Hsiao, MD, PhD Professor Division of Endocrinology and Metabolism University of California, San Francisco Director, UCSF Metabolic Bone Clinic	Researcher: Ipsen Pharmaceuticals, Ultragenyx.
Hope Newport, MA, CCLS Family Services Manager International FOP Association	No relevant financial relationship(s) to disclose.
Michelle Davis Executive Director, IFOPA	To be disclosed prior to presentation.
Lisa Gillooly Parent of a child with Fibrodysplasia Ossificans Progressiva	No relevant financial relationship(s) to disclose.
Sharon Kantanie Interview participant – Patient with FOP	No relevant financial relationship(s) to disclose.

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The PlatformQ Health Education, LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:

For additional information about the accreditation of this activity, please visit https://partnersed.com.

Technical Support:

For any technical issues or issues with your CME Certificate, please contact ClinicalSeriesLive at 877-394-1306 or at Support@ClinicalSeriesLive.com.

Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC in collaboration with the National Organization for Rare Disorders, Inc. (NORD) and International Fibrodysplasia Ossificans Progressiva Association (IFOPA).

ACKNOWLEDGEMENT

This activity is supported by an educational grant from Ipsen Biopharmaceuticals, Inc.

TUITION

Complimentary

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

ENDURING CREDIT DESIGNATION STATEMENT

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DATE OF RELEASE/EXPIRATION

Enduring Material
The enduring material will be available from January 27, 2023 to January 27, 2024.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

• Recognize the signs and symptoms of FOP and the impact of the disease on patient and family QoL
• Confirm FOP diagnosis by performing or referring for genetic testing
• Apply current clinical evidence and management guidelines to reduce and manage the occurrence of flare-ups and prevent or minimize ongoing ossification
• Describe the efficacy, safety, and place in treatment of emerging therapies for patients with FOP

TARGET AUDIENCE

The target audience for the activity are orthopedists, rare-bone specialists, rheumatologists, pediatric rheumatologists, and pediatricians.

ESTIMATED TIME TO COMPLETE

1 hour

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To participate in the activity, go to www.ClinicalSeriesLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Name of Faculty or Presenter	Reported Financial Relationship
Ellen Roy Elias, MD, FAAP, FACMG Professor, Pediatrics and Genetics Doctor, Special Care Clinic Children’s Hospital Colorado University of Colorado School of Medicine	Nothing to disclose
Richard Keen, MD, PhD, FRCP Professor in Metabolic Bone Disease Royal National Orthopaedic Hospital NHS Trust Stanmore, UK	Grant/Research Support: Incyte, Ipsen, Regeneron Speakers Bureau/Honoraria for non-CME: Ipsen Consultant/Advisory Board: Ipsen, Regeneron

The PIM planners and managers have nothing to disclose. The PlatformQ Health Education, LLC planners and others have nothing to disclose.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:

Please contact the Postgraduate Institute for Medicine at inquiries@pimed.com.

Technical Support:

For any technical issues or issues with your CME Certificate, please contact ClinicalSeriesLive at 877-394-1306 or at Support@ClinicalSeriesLive.com.